Jump to content

Rezvilutamide

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 01:01, 19 March 2022 (Add: s2cid. | Use this bot. Report bugs. | Suggested by Whoop whoop pull up | Category:Sulfur compounds | #UCB_Category 9/52). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Rezvilutamide
Clinical data
Other namesSHR3680
Drug classNonsteroidal antiandrogen
Identifiers
  • 4-[3-[4-[(2S)-2,3-dihydroxypropoxy]phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H20F3N3O4S
Molar mass479.47 g·mol−1
3D model (JSmol)
  • CC1(C(=O)N(C(=S)N1C2=CC=C(C=C2)OC[C@H](CO)O)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
  • InChI=1S/C22H20F3N3O4S/c1-21(2)19(31)27(15-4-3-13(10-26)18(9-15)22(23,24)25)20(33)28(21)14-5-7-17(8-6-14)32-12-16(30)11-29/h3-9,16,29-30H,11-12H2,1-2H3/t16-/m0/s1
  • Key:KRBMOYIWQCZVHA-INIZCTEOSA-N

Rezvilutamide (INNTooltip International Nonproprietary Name;[1][2] developmental code name SHR3680) is a nonsteroidal antiandrogen which is under development by Jiangsu Hengrui Medicine for the treatment of prostate cancer and breast cancer.[3][4] It is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide.[3][4] As of October 2020, rezvilutamide is in phase 3 clinical trials for prostate cancer.[3] Other structural analogues of rezvilutamide besides enzalutamide include apalutamide and proxalutamide.

See also

References

  1. ^ "Rezvilutamide". chemidplus. U.S. National Library of Medicine.
  2. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO.
  3. ^ a b c "SHR 3680". AdisInsight.
  4. ^ a b Qin X, Han W, Luo H, Du C, Zou Q, Sun Z, et al. (2020). "SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study". Journal of Clinical Oncology. 38 (6_suppl): 90. doi:10.1200/JCO.2020.38.6_suppl.90. S2CID 214027454.
Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Rezvilutamide&oldid=1077937900"